Analysis showed that PFS was better in the pirtobrutinib group compared with the bendamustine group, with 24-month PFS rates of 93.4% and 70.7%, respectively. More work will be needed to determine the ...

When larger banks stepped out of the reverse mortgage market in the 2010s, Finance of America gobbled up much of the demand and became the second-largest reverse mortgage provider after Mutual of ...

Zanubrutinib demonstrates prolonged progression-free survival in relapsed/refractory CLL/SLL, with a median PFS of 52.5 months and 49.9 months for patients with del17p. The ALPINE trial confirms ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Pirtobrutinib significantly improved progression-free survival in treatment-naive CLL/SLL patients, reducing disease progression risk by 80% compared to bendamustine plus rituximab. The trial ...

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...

When it comes to hard problems, computer scientists seem to be stuck. Consider, for example, the notorious problem of finding the shortest round-trip route that passes through every city on a map ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...